shoulder pain; shoulder pain has developed into more general rotator cuff syndrome - pain on all shoulder movements; this is a spontaneous report received from a contactable reporter(s) (physician) from the regulatory agency (ra). regulatory number: gb-mhra-webcovid-202202140909306660-lebck (ra). other case identifier(s): gb-mhra-adr 26600263 (ra). a 69 year-old male patient received bnt162b2 (comirnaty), administration date 02oct2021 (lot number: ff8222) as dose 3 (booster), single for covid-19 immunisation. relevant medical history included: "primary prevention" (unspecified if ongoing); "prostatism" (unspecified if ongoing); "atrial arrhythmia" (unspecified if ongoing). concomitant medication(s) included: atorvastatin taken for prophylaxis, start date: 2019; dutasteride taken for prostatism, start date: 2019; rivaroxaban taken for arrhythmia supraventricular, start date: 2019; tamsulosin taken for prostatism, start date: 2019. vaccination history included: covid-19 mrna vaccine biontech (dose 1), administration date: 20dec2020, for routine vaccination; covid-19 mrna vaccine biontech (dose 2), administration date: 10jan2021, for routine vaccination. the following information was reported: arthralgia (disability) with onset 03oct2021, outcome "not recovered", described as "shoulder pain"; rotator cuff syndrome (disability) with onset 03oct2021, outcome "not recovered", described as "shoulder pain has developed into more general rotator cuff syndrome - pain on all shoulder movements". patient has not had symptoms associated with covid-19 not had a covid-19 test. clinical course: shoulder pain has developed into more general rotator cuff syndrome - pain on all shoulder movements. patient has not tested positive for covid-19 since having the vaccine. patient is not enrolled in clinical trial. the report dose not relate to possible blood clots or low platelet counts. the report dose not relate to possible myocarditis or pericarditis. no follow-up attempts are possible. no further information is expected